$ARWR
ARROWHEAD PHARMACEUTICALS, INC. Stock $arwr

$arwr Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-K Financial Statement

#000156459018030805 Filed on December 11, 2018

Income Statement

Concept	2018 Q3	2018 Q2	2018 Q1
Revenue	$11.26M	$727.4K	$650.1K
YoY Change	29.16%	-92.21%	-92.77%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.430M	$4.590M	$3.680M
YoY Change	-32.53%	-34.33%	-47.05%
% of Gross Profit
Research & Development	$15.99M	$12.05M	$12.00M
YoY Change	93.12%	74.38%	4.93%
% of Gross Profit
Depreciation & Amortization	$1.200M	$751.1K	$1.200M
YoY Change	0.0%	-31.72%	0.0%
% of Gross Profit
Operating Expenses	$22.42M	$16.65M	$15.68M
YoY Change	18.25%	10.56%	3.76%
Operating Profit	-$11.17M	-$15.92M	-$15.03M
YoY Change	8.96%	178.6%	145.27%
Interest Expense	$400.0K	$313.7K	$168.3K
YoY Change	-183.33%	138.81%	54.81%
% of Operating Profit
Other Income/Expense, Net	$10.00K	$313.7K
YoY Change
Pretax Income	-$10.76M	-$15.61M	-$14.88M
YoY Change	0.28%	182.73%	146.36%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$10.76M	-$15.61M	-$14.88M
YoY Change	0.26%	182.73%	146.32%
Net Earnings / Revenue	-95.6%	-2145.53%	-2289.45%
Basic Earnings Per Share	-$0.12	-$0.18	-$0.18
Diluted Earnings Per Share	-$0.12	-$0.18	-$0.18
COMMON SHARES
Basic Shares Outstanding		87.63M	84.08M
Diluted Shares Outstanding			84.08M

Balance Sheet

Concept	2018 Q3	2018 Q2	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$76.50M	$60.50M	$91.50M
YoY Change	16.62%	-19.44%	5.66%
Cash & Equivalents	$30.13M	$28.00M	$69.80M
Short-Term Investments	$46.40M	$32.50M	$21.70M
Other Short-Term Assets	$640.1K	$1.400M	$1.100M
YoY Change	-52.92%	-22.22%	-54.17%
Inventory
Prepaid Expenses	$1.268M
Receivables	$327.4K	$0.00	$0.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$78.77M	$61.90M	$92.70M
YoY Change	16.0%	-20.54%	3.34%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.94M	$14.00M	$14.60M
YoY Change	-10.17%	-13.04%	-7.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$17.70M
YoY Change
Other Assets	$141.9K	$100.0K	$100.0K
YoY Change	0.0%	-50.0%	-50.0%
Total Long-Term Assets	$32.84M	$51.00M	$34.30M
YoY Change	-9.08%	37.1%	-7.8%
TOTAL ASSETS
Total Short-Term Assets	$78.77M	$61.90M	$92.70M
Total Long-Term Assets	$32.84M	$51.00M	$34.30M
Total Assets	$111.6M	$112.9M	$127.0M
YoY Change	7.29%	-1.91%	0.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.806M	$2.200M	$1.800M
YoY Change	-31.16%	-31.25%	-30.77%
Accrued Expenses	$5.043M	$3.300M	$5.000M
YoY Change	10.48%	10.0%	66.67%
Deferred Revenue	$600.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$200.0K	$200.0K	$200.0K
YoY Change	0.0%	0.0%	0.0%
Total Short-Term Liabilities	$12.36M	$7.100M	$9.100M
YoY Change	-33.88%	-65.02%	-67.03%
LONG-TERM LIABILITIES
Long-Term Debt	$2.100M	$2.200M	$2.200M
YoY Change	-8.7%	-8.33%	-8.33%
Other Long-Term Liabilities	$200.0K	$1.900M	$1.900M
YoY Change	-90.48%	-32.14%	-47.22%
Total Long-Term Liabilities	$4.004M	$4.100M	$4.100M
YoY Change	-9.0%	-21.15%	-31.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.36M	$7.100M	$9.100M
Total Long-Term Liabilities	$4.004M	$4.100M	$4.100M
Total Liabilities	$16.37M	$10.60M	$12.70M
YoY Change	-27.57%	-57.6%	-61.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$487.3M
YoY Change	12.58%
Common Stock	$583.1M	$180.2K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$95.80M	$102.3M	$114.3M
YoY Change
Total Liabilities & Shareholders Equity	$111.6M	$112.9M	$127.0M
YoY Change	7.29%	-1.91%	0.08%

Cashflow Statement

Concept	2018 Q3	2018 Q2	2018 Q1
OPERATING ACTIVITIES
Net Income	-$10.76M	-$15.61M	-$14.88M
YoY Change	0.26%	182.73%	146.32%
Depreciation, Depletion And Amortization	$1.200M	$751.1K	$1.200M
YoY Change	0.0%	-31.72%	0.0%
Cash From Operating Activities	-$2.700M	-$14.40M	-$15.40M
YoY Change	-70.65%	38.46%	7.69%
INVESTING ACTIVITIES
Capital Expenditures	-$700.0K	-$200.0K	-$400.0K
YoY Change	600.0%	-81.82%	-71.43%
Acquisitions
YoY Change
Other Investing Activities	$4.000M	-$28.70M	$17.20M
YoY Change	-197.56%	143.22%	-169.35%
Cash From Investing Activities	$3.300M	-$28.90M	$16.80M
YoY Change	-178.57%	124.03%	-164.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.600M	1.500M	56.90M
YoY Change	-1700.0%		28350.0%
NET CHANGE
Cash From Operating Activities	-2.700M	-14.40M	-15.40M
Cash From Investing Activities	3.300M	-28.90M	16.80M
Cash From Financing Activities	1.600M	1.500M	56.90M
Net Change In Cash	2.200M	-41.80M	58.30M
YoY Change	-116.3%	79.4%	-244.67%
FREE CASH FLOW
Cash From Operating Activities	-$2.700M	-$14.40M	-$15.40M
Capital Expenditures	-$700.0K	-$200.0K	-$400.0K
Free Cash Flow	-$2.000M	-$14.20M	-$15.00M
YoY Change	-78.02%	52.69%	16.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	56585035
CY2016Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	95024259
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30133213
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	8454607
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	7891595
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	11595816
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4699275
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4690440
CY2016	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3260045
CY2018	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-383075
CY2017	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	43519
CY2016	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-231902
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	259578
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7203
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	75000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-319166
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2814509
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1020734
CY2018	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-414293
CY2017	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-274752
CY2016	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	131143
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47223417
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23938972
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-64427486
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1421252
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7918198
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3860237
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-48644218
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12055309
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55131817
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24838567
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	327375
CY2017Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	67797
CY2018Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1267717
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	141918
CY2018Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3937605
CY2017Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3399679
CY2018Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	307334
CY2017Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	867363
CY2018Q3	us-gaap	Other Assets Current OtherAssetsCurrent	640117
CY2017Q3	us-gaap	Other Assets Current OtherAssetsCurrent	1359638
CY2018Q3	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	46400176
CY2017Q3	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	40769539
CY2018Q3	us-gaap	Assets Current AssetsCurrent	78768598
CY2017Q3	us-gaap	Assets Current AssetsCurrent	67902904
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13935425
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15513019
CY2018Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	18764010
CY2017Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	20464439
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	141918
CY2018Q3	us-gaap	Assets Assets	111609951
CY2017Q3	us-gaap	Assets Assets	104022280
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2806098
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4076514
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5043087
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4564507
CY2017Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	440580
CY2018Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	600
CY2017Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5269741
CY2017Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	695114
CY2017Q3	us-gaap	Notes Payable Current NotesPayableCurrent	208506
CY2017Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	46407
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	18701048
CY2018Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1702801
CY2017Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1929052
CY2018Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	2101198
CY2017Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	2325018
CY2017	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	197790
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	17308000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	13447763
CY2018	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	208506
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-81720602
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2400
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2400
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2400
CY2018	us-gaap	Profit Loss ProfitLoss	-54450478
CY2017	us-gaap	Profit Loss ProfitLoss	-34380295
CY2016	us-gaap	Profit Loss ProfitLoss	-81723002
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.47
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.34
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	61050880
CY2016	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2050817
CY2016	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-5862464
CY2016	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-301022
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1312524
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	57352
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2618014
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	22124
CY2018	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember
CY2017	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember
CY2016	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember
CY2015Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	109621634
CY2016	arwr	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	3691398
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	133869
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11595816
CY2016	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-670765
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	271931
CY2017	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-403261
CY2017	arwr	Exchange Rights Exercised During Period Value ExchangeRightsExercisedDuringPeriodValue	17150
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8454607
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2656710
CY2018	arwr	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	1237429
CY2018	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-54668
CY2018Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5.25
CY2018	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-5269140
CY2017	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	157981
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	5000000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1270416
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3509995
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2554802
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1016506
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-401777
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-871833
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	52083131
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	44974736
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	46069420
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	4248716
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7434963
CY2016	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	217549
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	54667
CY2017	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	438838
CY2016	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	634187
CY2018	arwr	Proceeds From Exercises Of Warrants And Stock Options ProceedsFromExercisesOfWarrantsAndStockOptions	3631164
CY2017	arwr	Proceeds From Exercises Of Warrants And Stock Options ProceedsFromExercisesOfWarrantsAndStockOptions	272818
CY2016	arwr	Proceeds From Exercises Of Warrants And Stock Options ProceedsFromExercisesOfWarrantsAndStockOptions	3752120
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	56585035
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12419119
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	52231433
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	59953026
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-60527881
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4152094
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85366448
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81214354
CY2018	us-gaap	Interest Paid Net InterestPaidNet	173381
CY2017Q3	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	40434784
CY2017	us-gaap	Interest Paid Net InterestPaidNet	187647
CY2016	us-gaap	Interest Paid Net InterestPaidNet	11287
CY2016	arwr	Property And Equipment Purchased Through Tenant Improvement Allowance Financing PropertyAndEquipmentPurchasedThroughTenantImprovementAllowanceFinancing	4849360
CY2016	arwr	Property And Equipment Expenditures Included In Accounts Payable And Accrued Expenses PropertyAndEquipmentExpendituresIncludedInAccountsPayableAndAccruedExpenses	4801930
CY2017	arwr	Proceeds From Refundable Income Tax Credits ProceedsFromRefundableIncomeTaxCredits	3635016
CY2016	arwr	Proceeds From Refundable Income Tax Credits ProceedsFromRefundableIncomeTaxCredits	1365288
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	2400
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	2400
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	2400
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk—The Company maintains several bank accounts primarily at two financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. </p>
CY2018	arwr	Increase Decrease In Cash And Investments IncreaseDecreaseInCashAndInvestments	10900000
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0
CY2018Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0
CY2017Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0
CY2017Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	600334
CY2017Q3	arwr	Research Equipment ResearchEquipment	9660960
CY2017Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	132078
CY2017Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	12208380
CY2017Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	22601752
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7088733
CY2018	us-gaap	Depreciation Depreciation	2998846
CY2017	us-gaap	Depreciation Depreciation	2990010
CY2016	us-gaap	Depreciation Depreciation	1545733
CY2018Q3	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	46400176
CY2018Q3	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	429050
CY2018Q3	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	45971126
CY2017Q3	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	40769539
CY2017Q3	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	334755
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1700429
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1700429
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1714313
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1700429
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1700429
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1700429
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1700429
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1700429
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	10261865
CY2018Q3	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	150000000
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1288000
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1441000
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	839000
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1435409
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1044431
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1070496
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1097168
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1124445
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	3544882
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	9316831
CY2018Q3	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	223820
CY2018Q3	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	240258
CY2018Q3	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	257903
CY2018Q3	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	276845
CY2018Q3	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	297177
CY2018Q3	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	1029015
CY2018Q3	us-gaap	Contractual Obligation ContractualObligation	2325018
CY2018Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0
CY2018Q3	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	20100000
CY2018Q3	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	7400000
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5524399
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3998427
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.00
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.97
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	6.83
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.39
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.62
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5549543
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	822000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	242533
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	604611
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.14
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y1M6D
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	72152284
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	50361428
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0205
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0134
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0105
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0299
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0231
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0189
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.10
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.79
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.89
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M6D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.04
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.33
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.58
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	At vesting, each outstanding RSU will be exchanged for one share of the Company’s Common Stock. RSU recipients may elect to net share settle upon vesting, in which case the Company pays the employee’s income taxes due upon vesting and withholds a number of shares of Common Stock of equal value. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.
CY2018Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1085908
CY2017Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1337619
CY2018Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4188368
CY2017Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5670468
CY2018Q3	arwr	Deferred Tax Assets In Process Research And Development Cost DeferredTaxAssetsInProcessResearchAndDevelopmentCost	1227137
CY2017Q3	arwr	Deferred Tax Assets In Process Research And Development Cost DeferredTaxAssetsInProcessResearchAndDevelopmentCost	2196542
CY2018Q3	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	404836
CY2017Q3	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	203477
CY2018Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	114142741
CY2017Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	132119837
CY2018Q3	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	3854752
CY2017Q3	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	5358700
CY2017Q3	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1068206
CY2018Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	566535
CY2017Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	865675
CY2018Q3	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	709779
CY2017Q3	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	1020162
CY2018Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	126180056
CY2017Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	149840686
CY2018Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	116875075
CY2017Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	136625436
CY2018Q3	arwr	Deferred Tax Liabilities State Taxes DeferredTaxLiabilitiesStateTaxes	9304981
CY2017Q3	arwr	Deferred Tax Liabilities State Taxes DeferredTaxLiabilitiesStateTaxes	13215250
CY2018Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	9304981
CY2017Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	13215250
CY2018Q3	arwr	Percentage Of Valuation Allowance PercentageOfValuationAllowance	1.00
CY2017Q3	arwr	Federal Net Operating Loss Carry Forward FederalNetOperatingLossCarryForward	284800000
CY2018	arwr	Federal Estimated Net Operating Loss Carry Forward FederalEstimatedNetOperatingLossCarryForward	62800000
CY2017Q3	arwr	State Net Operating Loss Carry Forwards StateNetOperatingLossCarryForwards	196600000
CY2018	arwr	State Estimated Net Operating Loss Carry Forward StateEstimatedNetOperatingLossCarryForward	62800000
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2400
CY2018	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	2400
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.079
CY2018	arwr	Effective Income Tax Rate Reconciliation Deductions Stock Compensation Percent EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent	-0.026
CY2018	arwr	Effective Income Tax Rate Reconciliation Mark To Market Adjustments EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments	0.002
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.362
CY2017	arwr	Effective Income Tax Rate Reconciliation True Up On Deferred Taxes EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxes	-0.030
CY2017	arwr	Effective Income Tax Rate Reconciliation State Blended Rate Change EffectiveIncomeTaxRateReconciliationStateBlendedRateChange	-0.057
CY2018	arwr	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Percent EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent	-0.679
CY2017	arwr	Effective Income Tax Rate Reconciliation Nondeductible Income Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleIncomeExpenseOther	-0.022
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2017Q4	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2018	arwr	Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit	37000000
CY2017	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	426470
CY2016	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	476835
CY2017Q4	us-gaap	Revenues Revenues	3509821
CY2018Q1	us-gaap	Revenues Revenues	650125
CY2018Q2	us-gaap	Revenues Revenues	727375
CY2018Q3	us-gaap	Revenues Revenues	11255000
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-13813348
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15034059
CY2017Q4	us-gaap	Profit Loss ProfitLoss	-13198878
CY2018Q1	us-gaap	Profit Loss ProfitLoss	-14884311
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2016Q4	us-gaap	Revenues Revenues	4365496
CY2017Q1	us-gaap	Revenues Revenues	8985930
CY2017Q2	us-gaap	Revenues Revenues	9342498
CY2017Q3	us-gaap	Revenues Revenues	8713785
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-14901887
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6129642
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5714164
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10250216
CY2016Q4	us-gaap	Profit Loss ProfitLoss	-12086108
CY2017Q1	us-gaap	Profit Loss ProfitLoss	-6042557
CY2017Q2	us-gaap	Profit Loss ProfitLoss	-5519741
CY2017Q3	us-gaap	Profit Loss ProfitLoss	-10731889
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14

Files In Submission

Name	View Source	Status
0001564590-18-030805-index-headers.html	Edgar Link	pending
0001564590-18-030805-index.html	Edgar Link	pending
0001564590-18-030805.txt	Edgar Link	pending
0001564590-18-030805-xbrl.zip	Edgar Link	pending
arwr-10k_20180930.htm	Edgar Link	pending
arwr-20180930.xml	Edgar Link	completed
arwr-20180930.xsd	Edgar Link	pending
arwr-20180930_cal.xml	Edgar Link	unprocessable
arwr-20180930_def.xml	Edgar Link	unprocessable
arwr-20180930_lab.xml	Edgar Link	unprocessable
arwr-20180930_pre.xml	Edgar Link	unprocessable
arwr-ex211_9.htm	Edgar Link	pending
arwr-ex231_10.htm	Edgar Link	pending
arwr-ex311_11.htm	Edgar Link	pending
arwr-ex312_7.htm	Edgar Link	pending
arwr-ex321_8.htm	Edgar Link	pending
arwr-ex322_6.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gils0w0evnf0000001.jpg	Edgar Link	pending
gils0w0evnf0000002.jpg	Edgar Link	pending
gils0w0evnf0000003.jpg	Edgar Link	pending
gils0w0evnf0000004.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARWR
ARROWHEAD PHARMACEUTICALS, INC. Stock $arwr

2018 Q3 Form 10-K Financial Statement

#000156459018030805 Filed on December 11, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARWR ARROWHEAD PHARMACEUTICALS, INC. Stock $arwr

2018 Q3 Form 10-K Financial Statement

#000156459018030805 Filed on December 11, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARWR
ARROWHEAD PHARMACEUTICALS, INC. Stock $arwr